2,280 Shares in Medpace Holdings, Inc. $MEDP Bought by Kendall Capital Management

Kendall Capital Management purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 2,280 shares of the company’s stock, valued at approximately $1,207,000.

Several other large investors have also added to or reduced their stakes in the company. Johnson Financial Group Inc. purchased a new position in shares of Medpace in the second quarter worth about $27,000. Geneos Wealth Management Inc. boosted its position in Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company’s stock valued at $29,000 after buying an additional 37 shares during the last quarter. Elyxium Wealth LLC purchased a new stake in Medpace in the fourth quarter valued at approximately $30,000. Allied Private Wealth LLC acquired a new position in Medpace in the 2nd quarter worth approximately $31,000. Finally, Kilter Group LLC acquired a new position in Medpace in the 2nd quarter worth approximately $31,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling

In other Medpace news, Director Brian T. Carley sold 5,000 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $608.63, for a total transaction of $3,043,150.00. Following the completion of the transaction, the director owned 27,825 shares of the company’s stock, valued at $16,935,129.75. This represents a 15.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO August J. Troendle sold 27,174 shares of the firm’s stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $618.79, for a total value of $16,814,999.46. Following the completion of the transaction, the chief executive officer owned 561,195 shares in the company, valued at approximately $347,261,854.05. This trade represents a 4.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 122,261 shares of company stock worth $71,729,129 in the last quarter. 20.50% of the stock is owned by insiders.

Analysts Set New Price Targets

Several brokerages have commented on MEDP. Leerink Partners set a $620.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Weiss Ratings raised shares of Medpace from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, August 12th. Jefferies Financial Group downgraded shares of Medpace from a “buy” rating to a “hold” rating and boosted their target price for the company from $490.00 to $515.00 in a research report on Tuesday, July 7th. Barclays set a $600.00 price target on Medpace in a research report on Thursday, July 23rd. Finally, TD Cowen boosted their price objective on Medpace from $419.00 to $492.00 and gave the company a “hold” rating in a report on Friday, July 24th. Three analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace News Roundup

Here are the key news stories impacting Medpace this week:

• Positive Sentiment: Medpace’s latest earnings exceeded expectations, with quarterly EPS of $4.25 versus the $3.98 consensus estimate and revenue of $707.33 million versus $689.51 million expected. Revenue increased 17.2% year over year, while management maintained fiscal 2026 EPS guidance of $17.25 to $17.95. Why Is Medpace Up Since Its Last Earnings Report?
• Neutral Sentiment: Analyst sentiment remains mostly cautious. Three analysts rate Medpace a Buy and 10 rate it Hold, with a consensus price target of $584.18. Several firms raised their targets following the earnings report, but those targets remain below the stock’s recent trading level. Medpace Analyst Ratings and Price Targets
• Negative Sentiment: Several insiders sold shares on August 19–20. CEO August J. Troendle sold 42,783 shares for roughly $26.3 million, reducing his holdings by about 7% across the reported transactions. Directors Brian T. Carley and Fred B. Davenport Jr. sold 5,000 and 7,283 shares, respectively, reducing their positions by approximately 15% and 66%. While insider sales do not necessarily indicate deteriorating fundamentals, the cluster of transactions may weigh on investor sentiment. Medpace Insider Buying and Selling
• Negative Sentiment: Valuation is demanding, with Medpace trading at approximately 36 times earnings and a PEG ratio of 2.73. The stock is also near the upper end of its 52-week range, increasing sensitivity to profit-taking and any slowdown in growth.

Medpace Price Performance

Medpace stock opened at $620.75 on Friday. The stock has a market capitalization of $17.33 billion, a PE ratio of 36.39, a price-to-earnings-growth ratio of 2.77 and a beta of 1.15. The business has a 50 day simple moving average of $550.16 and a 200-day simple moving average of $492.71. Medpace Holdings, Inc. has a 12 month low of $373.00 and a 12 month high of $677.90.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Wednesday, July 22nd. The company reported $4.25 EPS for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to analyst estimates of $689.51 million. During the same quarter in the previous year, the firm earned $3.10 EPS. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, equities research analysts anticipate that Medpace Holdings, Inc. will post 17.54 EPS for the current fiscal year.

Medpace Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.